VEGF

Cataract surgery may raise diabetic macular oedema riskCataract surgery increases the risk of diabetic macular oedema (DMO), medical records from the United Kingdom suggest. An analysis of 4,850 eyes showed that the rate of DMO requiring treatment spiked about 4 months after the surgery.
Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Identifying common macular conditions with OCTEffectively manage patients through diagnosis and interpretation
Ranibizumab proves effective for DMO in NHS clinicsPatients treated for diabetic macular oedema with ranibizumab in the UK National Health Service (NHS) are getting benefits similar to those seen in clinical trials, according to a new study
Latest concepts in steroid therapy for diabetic macular oedemaSteroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
Do more anti-VEGF injections lead to better clinical outcomes?The appropriate use of agents that inhibit vascular endothelial growth factor (VEGF) can bring significant improvements to both short-term and long-term visual acuity for patients with neovascular AMD.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
New prevention and monitoring strategies for neovascular AMDNutritional supplements continue to be a viable prevention strategy for neovascular age-related macular degeneration (AMD), said Emily Chew, MD.
Investigational pipeline for DME looks promisingPharmacotherapy research for diabetic macular edema is looking at targets other than VEGF inhibition to develop treatments that can be used as standalone intervention or may be complementary to current options.
Year brings advances in retinal imaging, screening, and gene/drug therapiesThe topics of special interest to retina specialists during 2015 include optical coherence tomography angiography (OCTA) and screening for retinopathy of prematurity (ROP). Important research is taking place to determine the etiology of angiogenesis, possibly leading to targeting therapies in age-related macular degeneration (AMD), ROP, and diabetic retinopathy.